MX2022007624A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2022007624A
MX2022007624A MX2022007624A MX2022007624A MX2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A
Authority
MX
Mexico
Prior art keywords
combinations
disease
treating
compounds
condition
Prior art date
Application number
MX2022007624A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Duane Bunker
Fernando Donate
Peter Qinhua Huang
Ahmed Abdi Samatar
Jiali Li
Jianhui Ma
Sayee Gajanan Hegde
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022007624A publication Critical patent/MX2022007624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
MX2022007624A 2019-12-20 2020-12-16 Combinaciones. MX2022007624A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US202063009754P 2020-04-14 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
MX2022007624A true MX2022007624A (es) 2022-08-16

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007624A MX2022007624A (es) 2019-12-20 2020-12-16 Combinaciones.

Country Status (12)

Country Link
US (1) US20230042653A1 (enExample)
EP (1) EP4069224A4 (enExample)
JP (1) JP2023507799A (enExample)
KR (1) KR20220119428A (enExample)
CN (1) CN115103673A (enExample)
AU (1) AU2020408698A1 (enExample)
BR (1) BR112022012286A2 (enExample)
CA (1) CA3165477A1 (enExample)
IL (1) IL294084A (enExample)
MX (1) MX2022007624A (enExample)
TW (1) TW202135810A (enExample)
WO (1) WO2021127046A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CN101970440A (zh) * 2007-11-28 2011-02-09 先灵公司 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
EP2477628B1 (en) * 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
SG11202003974XA (en) * 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
KR20220044528A (ko) * 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제

Also Published As

Publication number Publication date
AU2020408698A1 (en) 2022-07-14
BR112022012286A2 (pt) 2022-08-30
KR20220119428A (ko) 2022-08-29
WO2021127046A1 (en) 2021-06-24
CN115103673A (zh) 2022-09-23
US20230042653A1 (en) 2023-02-09
TW202135810A (zh) 2021-10-01
CA3165477A1 (en) 2021-06-24
IL294084A (en) 2022-08-01
EP4069224A1 (en) 2022-10-12
EP4069224A4 (en) 2023-12-20
JP2023507799A (ja) 2023-02-27

Similar Documents

Publication Publication Date Title
MX2022007628A (es) Combinaciones.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2022007626A (es) Combinaciones.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2023008954A (es) Inhibidores de los receptores erbb.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PH12021552482A1 (en) Compounds targeting prmt5
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
EA202193015A1 (ru) Ингибиторы cdk
CR20240296A (es) Inhibidores parp1
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
MX2022007623A (es) Combinaciones.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX2021010321A (es) Compuestos macrociclicos.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2022007629A (es) Combinaciones.
PH12021552513A1 (en) Pyrrole compounds
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
PH12021552953A1 (en) Tricyclic compounds
WO2018005444A3 (en) Methods for treating cancer
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression